Amgen (AMGN) Receivables (2009 - 2026)

Amgen (AMGN) has reported Receivables for 18 consecutive years, with $9.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 12.37% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (up 12.37% YoY), while the FY2025 annual figure was $9.6 billion, up 37.11% from the prior year.
• Receivables came in at $9.1 billion for Q1 2026 at Amgen, down from $9.6 billion in the prior quarter.
• The five-year high for Receivables was $9.6 billion in Q4 2025, with the low at $5.1 billion in Q1 2022.
• Average Receivables over 5 years is $7.0 billion, with a median of $6.9 billion recorded in 2024.
• Across the five-year window, Receivables dropped 10.17% in 2024 and soared 37.11% in 2025, its largest moves.
• Year by year, Receivables stood at $5.7 billion in 2022, then jumped by 36.51% to $7.8 billion in 2023, then dropped by 10.17% to $7.0 billion in 2024, then jumped by 37.11% to $9.6 billion in 2025, then decreased by 4.51% to $9.1 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $9.1 billion, $9.6 billion, and $8.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.